{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-24-000004","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.549184+00:00","generated_at":"2026-06-05T09:15:25.321632+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viatris FY23 rev $15.4B, adj EBITDA $5.1B; 2024 guidance; $1B buyback boost; Idorsia deal","bullets":["FY23 total revenues $15.4B, U.S. GAAP net earnings $54.7M, adjusted EBITDA $5.1B, free cash flow $2.4B.","Reports third consecutive quarter of operational revenue growth on divestiture-adjusted basis; expects continued growth in 2024.","Enters global R&D collaboration with Idorsia for two Phase 3 assets selatogrel and cenerimod with blockbuster potential.","Board increases share repurchase authorization by $1B to $2B; maintains $0.48 annual dividend, declares $0.12 Q1 dividend.","Completed $250M in share repurchases in 2024 to date; guidance for 2024 provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-24-000004","json":"https://secwatch.observer/filing/0001792044-24-000004.json","markdown":"https://secwatch.observer/filing/0001792044-24-000004.md","text":"https://secwatch.observer/filing/0001792044-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204424000004/0001792044-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204424000004/vtrs-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:15:25.321632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8528661a2d0aa8bdb4de282a7211c8cc05a73b8b","claim":"Viatris Inc reported fourth quarter and full year 2023 results: revenue $15.4 Billion, net income $54.7 Million.","evidence_excerpt":"Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance • Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] • Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1 Billion, U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204424000004/0001792044-24-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Revenue","value":"$15.4 Billion"},{"label":"Net income","value":"$54.7 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}